Theseus Pharmaceuticals, Inc. Profile

Industry
Biotechnology
Sector
Healthcare
Number of Employees
38

seus Pharmaceuticals's Business Model

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

About seus Pharmaceuticals

Website: https://theseusrx.com

CEO (Chief Executive Officer): Dr. Iain D. Dukes DPHIL, M.A.

IPO date: 2021-10-07

Contact

Country: US

Address: 245 Main Street

City: Cambridge

State: MA

Phone: 857 400 9491

Zip Code: 02142

Other

CIK: 0001745020

ISIN: US88369M1018

CUSIP: 88369M101

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.